Customize
Quick Links
Specialties

Accreditation/Designation of Credit

Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians' Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669 for 1.5 Contact Hours.

Acknowledgment of Commercial Support

This activity is supported by educational grants from AbbVie; AstraZeneca; Boehringer Ingelheim Pharmaceuticals, Inc; Genentech; Ignyta; Merck Sharp & Dohme Corp; Novartis Pharmaceuticals Corporation; and Takeda Oncology.

Online Medical Crossfire®: 5th Annual Miami Lung Cancer Conference

Release Date: May 30, 2018
Expiration Date: May 30, 2019
Media: Internet - based

 

Activity Overview

This edition of Medical Crossfire®, filmed in conjunction with the 5th Annual Miami Lung Cancer Conference®, is designed to provide a dynamic discussion of current and evolving paradigms in the treatment of lung cancer, including immunotherapies in development, molecular subsets and targeted agents, the emergence of liquid biopsies, and the management of patients without actionable mutations.

Our program co-chairs, Heather A. Wakelee, MD, and Julie Brahmer, MD, and our expert faculty, Christina Baik, MD, MPH; Justin F. Gainor, MD; Sarah B. Goldberg, MD, MPH; Rebecca S. Heist, MD, MPH; Gilberto de Lima Lopes Jr, MD, MBA, FAMS; Christine M. Lovly, MD, PhD; Jarushka Naidoo, MB BCH; Sukhmani K. Padda, MD; and Rathi Pillai, MD, emphasize the cutting-edge clinical research that will shape the therapy of lung cancer in the near future. Our community oncology representatives, Luis E. Raez, MD, FACP, FCCP and Estelamari Rodriguez, MD, MPH, complement the academic perspective provided by our faculty.

Each 10-minute presentation will be followed by an extensive question-and-answer segment led by Dr. Wakelee or Dr. Brahmer. This discussion format will allow ample time for examining the nuances and challenges faced by clinicians in everyday practice and include a discussion of strategies for applying emerging data to clinical practice to improve outcomes for patients.

Acknowledgement of Commercial Support

This activity is supported by educational grants from AbbVie; AstraZeneca; Boehringer Ingelheim Pharmaceuticals, Inc; Genentech; Ignyta; Merck Sharp & Dohme Corp; Novartis Pharmaceuticals Corporation; and Takeda Oncology.

Requirements for Successful Completion

  • You will need to login to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review videos/content until you finish the presentation.
  • At the end of the activity, “educational content/video” will be available for your reference.
  • In order to receive a CME/CE certificate, participants must complete the activity.
  • Complete the posttest and pass with a score of 70% or higher, complete the evaluation and then click on request for credit. Participants may immediately download a CME/CE certificate upon completion of these steps.


Target Audience

This educational activity is directed toward oncologists involved in the treatment and management of patients with lung cancers. Nurse practitioners (NPs), nurses, physician assistants (PAs), pharmacists, researchers, fellows, and other healthcare professionals interested in the treatment of lung cancers may also participate.

Learning Objectives

At the conclusion of this activity, you should be better prepared to:

  • Apply testing approaches to inform clinical decision making for the treatment of advanced non–small cell lung cancer (NSCLC) in multiple lines of care
  • Report key clinical trial findings on the use of immunotherapeutic strategies in locally advanced and advanced forms of NSCLC
  • Explain the application of chemotherapeutic and targeted approaches to facilitate sequencing in lung cancer care for tumors with or without oncogenic drivers
  • Determine evolving practices concerning the use of liquid biopsies along the disease continuum in the management of advanced NSCLC
  • Integrate methods to determine treatment approaches, monitor responses, and mitigate the impact of treatment-related toxicities for challenging case scenarios typically encountered in lung cancer management


Faculty, Staff, and Planners' Disclosures

Faculty

Christina Baik, MD, MPH
Thoracic, Head and Neck Medical Oncology
Seattle Cancer Care Alliance
Fred Hutchinson Cancer Research Center
University of Washington
Seattle, WA

Disclosure: Grant/Research Support: Celgene, Novartis, Clovis Oncology, Genentech, Loxo Oncology, Incyte, Millennium

Julie Brahmer, MD
Interim Director, Sidney Kimmel Comprehensive Cancer Center
Associate Professor of Oncology
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Baltimore, MD
 

Disclosure: Grant/Research Support: Bristol-Myers Squibb, MedImmune/AstraZeneca, Merck; Consultant: Bristol-Myers Squibb (uncompensated), Celgene, Lilly, Merck Sharp & Dohme Corp

Justin F. Gainor, MD
Instructor, Medicine, Harvard Medical School
Assistant in Medicine
Massachusetts General Hospital
Boston, MA
 

Disclosure: Consultant: Novartis, Bristol-Myers Squibb, Genentech, Theravance Biopharma, Loxo Oncology; Honoraria: Merck, Incyte

Sarah B. Goldberg, MD, MPH
Assistant Professor of Medicine (Medical Oncology)
Yale Cancer Center
New Haven, CT
 
 

Disclosure: Grant/Research Support: AstraZeneca

Rebecca S. Heist, MD, MPH
Assistant Professor, Department of Medicine, Harvard Medical School
Assistant Professor in Medicine
MGH Cancer Center, Massachusetts General Hospital
Boston, MA
 

Disclosure: Consultant: Boehringer Ingelheim

Gilberto de Lima Lopes Jr, MD, MBA, FAMS
Associate Professor of Clinical Medicine
Medical Director for International Programs
Associate Director for Global Oncology
Co-Leader, Lung Cancer Site Disease Group
Sylvester Comprehensive Cancer Center at the
University of Miami and the Miller School of Medicine
Miami, FL

Disclosure: No relevant financial relationships with commercial interests to disclose

Christine M. Lovly, MD, PhD
Assistant Professor of Medicine (Hematology/Oncology)
Assistant Professor of Cancer Biology
Vanderbilt University School of Medicine
Vanderbilt Ingram Cancer Center
Nashville, TN

Disclosure: Grant/Research Support: Novartis, Xcovery, AstraZeneca; Consultant: Novartis, Pfizer, Ariad Pharmaceuticals, Genoptix, AstraZeneca, Takeda, Foundation Medicine, Cepheid

Jarushka Naidoo, MB BCH
Assistant Professor of Oncology
Johns Hopkins University
Baltimore, MD
 
 

Disclosure: No relevant financial relationships with commercial interests to disclose

Sukhmani K. Padda, MD
Instructor of Medicine
Stanford University Medical Center
Stanford, CA
 
 

Disclosure: Consultant: AstraZeneca, G1 Therapeutics, and Janssen Pharmaceuticals

Rathi Pillai, MD
Assistant Professor
Department of Hematology and Medical Oncology
Winship Cancer Institute
Emory University School of Medicine
Atlanta, GA

Disclosure: Consultant: AstraZeneca

Luis E. Raez, MD, FACP, FCCP
Chief Hematology/Oncology &
Medical Director
Memorial Cancer Institute
Memorial Health Care System
Clinical Professor of Medicine
Herbert Wertheim College of Medicine
Florida International University Miami, FL

Disclosure: No relevant financial relationships with commercial interests to disclose

Estelamari Rodriguez, MD, MPH
Medical Director Thoracic Oncology
Chair, Women’s Centered Care Network
Mount Sinai Medical Center
Comprehensive Cancer Center
Miami Beach, FL

Disclosure: Consultant: Guardant; Speaker’s Bureau: Bristol-Myers Squibb, Genentech

Heather A. Wakelee, MD
Professor of Medicine (Oncology)
Stanford University Medical Center
Stanford, CA
 
 

Disclosure: Grant/Research Support: Clovis Oncology, Exelixis, AstraZeneca/MedImmune, Genentech/Roche, Bristol-Myers Squibb, Gilead, Novartis, Xcovery, Pfizer, Celgene, Pharmacyclics, Lilly; Consultant: ACEA, Genentech (uncompensated), Novartis

The staff of Physicians' Education Resource®, LLC have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME/CE activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME/CE activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME/CE activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME/CE activity is for continuing education purposes only, and is not meant to substitute for the independent medical judgment of a physician or nurse relative to diagnostic, treatment, or management options for a specific patient's medical condition.

The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any of the companies that provided commercial support for this activity.

PER Pulse Recap™

PER Pulse Recap (1 of 3)

Updates on Targeted Therapy in NSCLC
 
The 5th Annual Miami Lung Cancer Conference®, which was held on March 10, 2018, featured internationally recognized experts in thoracic malignancies. These experts, along with representatives from community practice, discussed key advances in the treatment of patients with lung cancer. This first of 3 PER Pulse™ Recaps from the Miami Lung Cancer Conference® focuses on recent developments for patients with oncogene-driven non–small cell lung cancer (NSCLC).
  • Osimertinib was approved in April 2018 for first-line therapy for patients with mutations in the EGFR gene. The initial results of the FLAURA trial provided the basis for this approval, with a benefit in progression-free survival (PFS) observed with osimertinib compared with gefitinib or erlotinib. Subsequent analyses have also shown improved activity in the central nervous system with osimertinib, as well as time from randomization to second disease progression. A second-generation epidermal growth factor receptor inhibitor, dacomitinib, is under review for first-line therapy, with a decision expected by September 2018. Finally, afatinib was approved in January 2018 for patients with less common EGFR mutations.
  • In June 2018, updated efficacy data were presented from the ALEX trial comparing alectinib with crizotinib as the initial anaplastic lymphoma kinase inhibitor for patients with ALK-rearranged NSCLC. The median investigator-assessed PFS was 34.8 months with alectinib and 10.9 months with crizotinib (HR, 0.43). In late July 2018, it was announced that the frontline ALTA-1L trial comparing brigatinib with crizotinib in patients with ALK-rearranged NSCLC had met the primary endpoint of PFS.
  • Targeted agents for emerging oncogenic drivers continue to be developed; in the case of NTRK and RET, potential applications in a wide range of tumor types have been suggested in early-phase clinical trials. Larotrectinib has been granted priority review for patients with NTRK-fusion–positive cancers, with a decision expected by November 2018. In the setting of RET fusions, several next-generation inhibitors, including LOXO-292, BLU-667, and RXDX-105, have demonstrated activity against various fusion partners in several tumor types, including NSCLC.

PER Pulse Recap (2 of 3)

New Developments for Immunotherapy in NSCLC

This second of 3 PER Pulse™ Recaps from the Miami Lung Cancer Conference® focuses on recent data on immunotherapy for patients with non–small cell lung cancer (NSCLC).
  • Single-agent immunotherapy in the first-line setting gained approval in 2016 for stage IV NSCLC, based on the KEYNOTE-024 trial enrolling patients with a PD-L1 expression level of ≥50%. In June 2018, results of a similar trial, KEYNOTE-042, were presented. The main difference in this trial was a lowered PD-L1 expression cutoff of ≥1%. Improved overall survival (OS) was observed for pembrolizumab compared with platinum-based chemotherapy in the overall cohort; however, in patients with a PD-L1 expression level of 1% to 49%, no benefit was observed, and the application of single-agent immunotherapy in patients with lower PD-L1 expression level is still not defined.
  • In patients with advanced, nonsquamous NSCLC, the KEYNOTE-189 trial has confirmed the results of the earlier phase II KEYNOTE-021 trial leading to the accelerated approval of pembrolizumab plus carboplatin-pemetrexed as initial therapy; full approval of the combination of pembrolizumab plus platinum-pemetrexed is anticipated by September 2018. Another trial, IMpower150, has demonstrated improved OS and progression-free survival (PFS) with the addition of pembrolizumab to bevacizumab plus carboplatin-paclitaxel; this combination is in priority review, with a decision expected by September 2018.
  • The KEYNOTE-407 trial has raised the potential for a new first-line standard of care for patients with advanced, squamous NSCLC. In this trial, the addition of pembrolizumab to carboplatin and paclitaxel or nab-paclitaxel yielded a significant improvement in OS and PFS. These data are also in priority review, with a decision expected by the end of October 2018.
  • Durvalumab was approved in February 2018 for patients with unresectable stage III NSCLC following response or stable disease after chemoradiation therapy, based on an improvement in PFS seen with durvalumab compared with placebo. In May 2018, it was announced that improved OS was also observed, with full data to be presented at a later date.

PER Pulse Recap (3 of 3)

New Agents in Development for SCLC

This third of 3 PER Pulse™ Recaps from the Miami Lung Cancer Conference® focuses on the development of new agents for patients with small cell lung cancer (SCLC).
  • Immunotherapy is becoming an established part of the treatment algorithm for patients with SCLC, with nivolumab with or without ipilimumab listed in treatment guidelines for patients with relapsed disease. Single-agent nivolumab was granted priority review by the FDA for patients with ≥2 prior lines of activity, with a decision deadline of August 16, 2018, based on results from the CheckMate 032 trial. Data from a phase III trial, IMpower133, have yet to be presented; however, in July 2018, it was announced that the addition of atezolizumab to carboplatin-etoposide improved both overall survival (OS) and progression-free survival in patients with chemotherapy-naïve, extensive-stage SCLC.
  • Novel cytotoxic agents are also in development. Lurbinectedin, an inhibitor of RNA polymerase II, was granted orphan drug status in August 2018 for patients with SCLC. In June 2018, results of a phase II trial of lurbinectedin in 68 patients with SCLC and a median of 1 prior line of therapy were presented. A response rate of 39% was observed, with a median OS of 11.8 months.
For additional commentary about this topic and others, visit gotoper.com to access additional resources from the 5th Annual Miami Lung Cancer Conference®, including downloadable slides from the meeting.








Become a Member

Forgot Password?
Filter By